HUTCHMED's Orpathys (savolitinib) approved by China's NMPA for gastric cancer
HUTCHMED (00013.HK) announced that its drug Orpathys (savolitinib) has received approval from China's National Medical Products Administration (NMPA) for the treatment of gastric cancer patients with MET amplification.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.